Literature DB >> 18582961

Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels.

Altan Onat1, Hakan Ozhan, Enver Erbilen, Sinan Albayrak, Zekeriya Küçükdurmaz, Günay Can, Ibrahim Keleş, Gülay Hergenç.   

Abstract

UNLABELLED: The role of plasma fibrinogen levels in predicting metabolic syndrome (MetS) and assessment of determinants of these levels were investigated. A total of 2234 men and women, aged 49+/-12 years, representative of Turkish adults who had plasma fibrinogen determinations, were prospectively evaluated and followed for a mean of 6.6 years. The modified Clauss method was used for assays. MetS was defined by ATPIII criteria modified for male abdominal obesity. MetS cases at baseline were excluded in prospective analyses. Median (interquartile range) fibrinogen values were 2.87 (2.29; 3.56) g/L. Fibrinogen levels predicted significantly newly developing MetS in men (RR 1.40 [95%CI 1.07; 1.83] for a 2-fold increment), after adjustment for age and smoking status, and (RR 1.32 [95%CI 0.95; 1.83] again for doubling), after additional adjustment for all 5 components of MetS. MetS was not significantly predicted by fibrinogen levels in women in either multivariable model. By regression analysis of eight covariates, not waist circumference, but systolic blood pressure, current smoking and C-reactive protein (CRP) in men, and age in women were predictors of elevated (>3.0 g/L) fibrinogen at follow-up (p<0.05 in all).
CONCLUSIONS: Plasma fibrinogen predicts MetS independently of its components in men, in contradistinction to women, and, hence, is likely one of its components. Hyperfibrinogenemia representing an inflammatory state is postulated as the underlying mechanism. Central obesity is linked to elevation in fibrinogen mainly through the mediation of blood pressure, CRP, and via being affected by cigarette smoking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582961     DOI: 10.1016/j.ijcard.2008.03.054

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Pharmacological treatment and therapeutic perspectives of metabolic syndrome.

Authors:  Soo Lim; Robert H Eckel
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

Review 2.  Effects of lifestyle interventions on inflammatory markers in the metabolic syndrome.

Authors:  Kristen M Beavers; Barbara J Nicklas
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

3.  Dynamics in Cardiometabolic Risk among Turkish Adults: Similarities to that in Iranians?

Authors:  Altan Onat
Journal:  Int J Prev Med       Date:  2011-04

Review 4.  Metabolic syndrome: definitions and controversies.

Authors:  Eva Kassi; Panagiota Pervanidou; Gregory Kaltsas; George Chrousos
Journal:  BMC Med       Date:  2011-05-05       Impact factor: 8.775

5.  Carotid intima-media thickness and plasma fibrinogen among subjects with metabolic syndrome: Isfahan cohort study, Iran.

Authors:  Zahra Bayanfar; Masoumeh Sadeghi; Ramin Heidari; Mojgan Gharipour; Mohammad Talaie; Akram Sedaghat
Journal:  ARYA Atheroscler       Date:  2014-09

6.  A new insight into the role of plasma fibrinogen in the development of metabolic syndrome from a prospective cohort study in urban Han Chinese population.

Authors:  Lijie Ding; Chengqi Zhang; Guang Zhang; Tao Zhang; Min Zhao; Xiaokang Ji; Zhongshang Yuan; Ruihong Liu; Fang Tang; Fuzhong Xue
Journal:  Diabetol Metab Syndr       Date:  2015-12-02       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.